drugset
drugset / Trial / NCT01218204

A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Administering Multiple Oral Doses of GSK1292263 Alone and With Atorvastatin

NCT01218204 ↗

Phase 2 Completed 287 enrolled GlaxoSmithKline
RandomizedParallel-groupTriple-blindTreatment

Summary

This study investigates the safety, pharmacokinetics and effects of GSK1292263 when taken alone or when co-dosed with atorvastatin to subjects with dyslipidemia.

Timeline

Start
2010-09-14
Primary completion
2011-06-29
Completion
2011-06-29

Drugs

EvaluationDrugModalityDoseRoute
Subject Atorvastatin Small molecule 10 mg Oral
Subject Atorvastatin Small molecule 80 mg Oral
Subject Ezetimibe Unknown 10 mg Oral
Subject GSK1292263 Small molecule 100 mg Oral
Subject GSK1292263 Small molecule 300 mg Oral
Subject GSK1292263 Small molecule 800 mg Oral

Indications

hyperlipidemia